In this webinar, we will walk you through the tools and techniques to help contract research organizations and pharma R&D scientists incorporate .. Read more automated purification technologies for hybridoma clonal selection, which will feed into novel antibody discovery at a fraction of the time, cost, and effort of traditional micro-extraction approaches. From titer estimation to quantitative binding, we will show you how automated micro-purification with dSPE will allow scientists to focus more time on discovery and spend less time handling samples or programming automated platforms. Join Kemp Proteins scientists Carter Mitchell, Chief Technology Officer, and Joe Corvera, Director of Hybridoma Development, as they talk about incorporating these tools into their workflow to prevent bottlenecks and increasing success. Carter Mitchell is a protein chemist and structural biologist with 20 years of direct experience isolating and characterizing difficult proteins from various recombinant and natural sources. He earned a PhD in Structural Biology where he enzymatically characterized and solved the structures of multidomain proteins involved in the biosynthesis of metabolites. Prior to joining Kemp Proteins, he was the Chief Technology Officer and Director of Structural Biology at a Biotech start-up where he built, developed, and implemented a protein expression and isolation laboratory and managed the protein production and purification team. Joe Corvera has more than 20 years of experience leading teams involved in protein and antibody development and production.
- Share your Experience
More Events From The Organizer
- Considering Australia as part ..19 Jan 2021Online